RADIOPHARM THERANOSTICS LTD

Radiopharm Theranostics reports dual clinical milestones for RAD101 and RAD204 while launching a $400 M capital raise to accelerate oncology radiopharmaceutical development.

Radiopharm Theranostics Limited is advancing oncology radiopharmaceuticals, announcing its upcoming presentation at the NWR Virtual Healthcare Conference to showcase its clinical‑stage biotech innovations.

Radiopharm Theranostics Limited, a biotech company based in Australia, is pioneering the development of radiopharmaceutical products to address high unmet medical needs and improve patient care and outcomes worldwide.